Untreated Resectable Non-Small Cell Lung Cancer

MADRID — The addition of nivolumab to neoadjuvant chemotherapy, followed by adjuvant nivolumab, improved outcomes for patients with untreated resectable non-small cell lung cancer, randomized phase 3 study results showed.